CorMedix to Participate in Upcoming Investor Conferences

(NasdaqGM:CRMD), BERKELEY HEIGHTS, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) — CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be presenting and participating in investor meetings at upcoming investor conferences taking place in September. Cantor Global Healthcare Conference […]

Mezrah Consulting Launches Their MSO Deferral Plan(TM) Strategy and Partner Platform

TAMPA, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) — Mezrah Consulting, a national executive benefits consulting firm, today announced the launch of its MSO Deferral Plan(TM) and Partnership Program. As part of Mezrah Consulting's continued commitment to innovation in creating new income deferral strategies and, in general, the executive benefits space, this new strategy builds on

Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference

(NASDAQ:APRE), DOYLESTOWN, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today announced that management will present at the H.C. Wainwright 27th Annual Global Investment Conference, to take place

CytoDyn to Present at the H.C. Wainwright 27th Annual Global Investment Conference

(Other OTC:CYDY),(OTC US:CYDY), VANCOUVER, Washington, Aug. 28, 2025 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a clinical-stage biotechnology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, today announced that management will participate in the H.C. Wainwright 27th Annual Global Investment Conference

ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Pioneering Innovative Mining Approach, Demonstrating Next-Gen Processing Capabilities

(Other OTC:ESAUF),(CNSX:ESAU),(CNSX:ESAU.CN),(OTC US:ESAUF),(Boerse Frankfurt – Freiverkehr:Z7D),(Boerse Frankfurt – Freiverkehr:Z7D.F), NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) — via InvestorWire — ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on

IBN Initiates Coverage of GlobalTech Corp.

(Other OTC:GLTK), AUSTIN, Texas, Aug. 28, 2025 (GLOBE NEWSWIRE) — GlobalTech Corp. (OTC: GLTK), a U.S.-based technology holding company specializing in artificial intelligence (AI), big data, and digital infrastructure, has selected IBN, a multifaceted financial news and publishing company serving private and public entities, to spearhead its corporate communications efforts. GlobalTech balances internal innovation with

Apollo to Present at the Barclays Global Financial Services Conference

(NYSE:APO), NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) — Apollo (NYSE: APO) today announced that Jim Zelter, President of Apollo Global Management, will participate in a fireside chat at the Barclays Global Financial Services Conference on Tuesday, September 9, 2025 at 9:45 am EDT. A live webcast of the event will be available on Apollo's

Vericel to Present at the Wells Fargo Healthcare Conference on Thursday, September 4, 2025

(NasdaqGM:VCEL), CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will participate in a fireside chat at the Wells Fargo Healthcare Conference at 3:45 p.m. ET on Thursday, September 4, 2025. A webcast of

Teva Announces FDA Approval and Launch of Generic Saxenda(R) (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss

(NYSE:TEVA),(TASE:TEVA.TA),(TASE:TEVA), Generic Saxenda(R) is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the U.S. market. This approval and launch add to Teva's continued commitment to its complex generic medicine portfolio as part of its Pivot to Growth Strategy. Liraglutide injection is indicated for adults with obesity

Sustainable Innovation & Health Dividend Fund Normal Course Issuer Bid

Sustainable Innovation & Health Dividend Fund Normal Course Issuer Bid GlobeNewswire August 28, 2025 TORONTO, Aug. 28, 2025 (GLOBE NEWSWIRE) — Sustainable Innovation & Health Dividend Fund (the “Fund”) (TSX: SIH.UN) announced that it has filed a notice with the Toronto Stock Exchange (the “TSX”) and received its approval to make a normal course issuer

Scroll to Top